Asgard Therapeutics was awarded with Sweden’s SWElife innovation grant. Swelife is a strategic innovation programe, funded by the Swedish Government via the Swedish innovation agency, Vinnova, and by the programe’s partners. Swelife supports collaboration within academia,
Rapidus and PwC highlighted Fábio Rosa as one of 34 young promising Scanian personalities and driven entrepreneurs of this year.
In a new survey published by Øresund Institute and Medicon Valley Alliance, Asgard Therapeutics was highlighted as one of 426 life science companies in Skåne. https://www.oresundsinstituttet.org/life-science-skane/?utm_campaign=unspecified&utm_content=unspecified&utm_medium=email&utm_source=apsis-anp-3
Mats Paulsson Foundations awarded Filipe Pereira, co-founder of Asgard Therapeutics, with a Mats Paulsson Grant 2020. Since 2019, the foundation has focused on grants for academic research projects that in
The KiiLN- Keystone for Incubating Innovation in Life Sciences Network team and Icahn School of Medicine at Mount Sinai awarded Filipe Pereira, co-founder of Asgard Therapeutics, the KiiLN Postdoctoral Entrepreneurship Award. This award
Asgard Therapeutics AB has been admitted to SmiLe Incubator as the next step to move forward on the pre-clinical studies of their lead program TrojanDC. https://news.smileincubator.com/posts/pressreleases/immunotherapy-company-asgard-therapeutics-is
Advanced Therapies Medical Products (ATMPs) are considered the “drugs of the future”. These are based on gene, cell and tissue products. Sweden has the ambitious goal of becoming a leader
Filipe Pereira, Cristiana Pires and Fábio Rosa, co-founders of Asgard Therapeutics, awarded with the Lund University and Sparbanken Skåne’s prize for future innovations
Together with Sparbanken Skåne, in collaboration with the Sparbanksstiftelsen Finn, Lund University awarded Filipe Pereira, Cristiana Pires and Fábio Rosa the Lund University and Sparbanken Skåne’s prize for future innovations.
The BioInnovation Institute (BII) awarded Filipe Pereira, co-founder of Asgard Therapeutics, with DKK 3.5M to advance pre-clinical development of dendritic cell reprogramming and define its regulatory roadmap towards the clinic.
Swedish start-up company Asgard Therapeutics has been awarded the second step of Vinnova’s Innovative Startup program in order to further develop a new cancer immunotherapy based on dendritic cell reprogramming.
Asgard was selected to receive Vinnova’s VFT+ funds managed by LU Innovation for verification activities of TrojanDC towards partners, customers and investors.
Fábio Rosa, co-founder of Asgard Therapeutics, selected for Forbes 30 under 30 List – Europe – Science & Healthcare 2020
Fábio Rosa, co-founder of Asgard Therapeutics, was selected by Forbes among 30 brightest young entrepreneurs, innovators and game changers in Science and Healthcare segment. https://www.forbes.com/profile/fabio-rosa/#7376307670f8